LAMA1 Antibody

What is the optimal validation strategy for confirming LAMA1 antibody specificity?

When validating LAMA1 antibody specificity, a multi-tiered approach is recommended:

• Knockout validation: Compare staining between wild-type and LAMA1 knockout samples. Search result demonstrates this approach using wild-type HeLa cells versus LAMA1 knockout HeLa cell lysate (ab258937), showing loss of signal in knockout cells.

• Peptide competition assay: Pre-incubate antibody with purified laminin-111 to block specific binding sites. As noted in search result , this verification method ensures signal specificity.

• Multiple antibody concordance: Test at least two antibodies targeting different LAMA1 epitopes. Search results show various antibodies targeting different regions: MAB4187 targets Leu22-Met269 , while ab210954 targets amino acids 600-700 .

• Cross-reactivity assessment: Test against related proteins to ensure specificity. According to search result , proper antibodies show "negligible cross-reactivity with Type I, II, III, IV, V or VI Collagens or Fibronectin."

What are the key considerations for immunohistochemical detection of LAMA1?

Successful IHC detection of LAMA1 requires addressing several technical considerations:

• Antigen retrieval: Heat-mediated antigen retrieval using Tris-EDTA buffer (pH 9.0) significantly improves LAMA1 detection. Search result specifies using "Antigen Retrieval Buffer (100X Tris-EDTA Buffer, pH 9.0) ab93684."

• Incubation conditions: Optimal results are achieved with overnight incubation at 4°C. Search result demonstrates: "The section was incubated with ab307542 at 4°C overnight."

• Antibody dilution: For paraffin-embedded sections, recommended dilutions vary by antibody. Search result suggests "2-5μg/ml" for their antibody, while result indicates a 1:200 dilution.

• Detection systems: HRP-polymer based secondary antibodies provide superior signal-to-noise ratio compared to standard secondaries. Search result specifies "Goat Anti-Rabbit IgG H&L (HRP polymer)" as the detection reagent.

• Counterstaining: Hematoxylin provides optimal nuclear contrast without obscuring LAMA1 signal. Result confirms: "Counterstained with Hematoxylin."

How should researchers optimize Western blot protocols for LAMA1 detection?

LAMA1 Western blotting presents unique challenges due to its high molecular weight (337 kDa):

• Sample preparation: Use protease inhibitor cocktails during cell/tissue lysis to prevent degradation of this large protein.

• Gel selection: Use low percentage (3-8%) gradient gels to properly resolve this high molecular weight protein. Standard 10% gels will not allow proper migration.

• Transfer conditions: Employ extended transfer times (overnight at 30V) or use specialized high-molecular-weight transfer systems.

• Blocking conditions: Search result recommends a 1:1000 dilution for Western blotting applications.

• Loading controls: Standard loading controls like β-actin (42 kDa) run off during the extended electrophoresis needed for LAMA1, so higher molecular weight controls like vinculin (124 kDa) are recommended. Search result specifically mentions using "mouse anti-Vinculin Antibody, clone V284 (EMD Millipore)" as a control.

• Band verification: Confirm the observed band is at the expected 337 kDa molecular weight, as reported in search results , , and .

What methodologies are most effective for investigating LAMA1's role in disease models?

Investigating LAMA1 in disease contexts requires specialized approaches:

• Conditional knockout systems: Employ Cre-loxP systems for tissue-specific deletion rather than global knockouts which are embryonic lethal. Search result describes how "homozygous Lama1 KO mice died by embryonic day 7 (E7)," necessitating conditional approaches.

• CRISPR activation (CRISPRa): For therapeutic investigation, CRISPRa provides a mechanism to upregulate endogenous LAMA1. Search result details a system "comprising single guide RNAs (sgRNAs) designed to target the proximal promoter region of LAMA1, VP64 transcriptional activators, and dCas9 derived from Staphylococcus aureus."

• Functional assays: Migration assays effectively measure LAMA1 functional outcomes. Result describes how "LAMA1 upregulation significantly decreased wound closure in all MDC1A fibroblasts," providing a quantifiable readout.

• Transcriptomic analysis: RNA-seq following LAMA1 manipulation reveals downstream pathway effects. Result mentions comparing "the transcriptomes of the M2 and M3 cells that were left untreated" versus those with modified LAMA1 expression.

• Protein-protein interaction studies: Co-immunoprecipitation with LAMA1 antibodies can identify binding partners in disease contexts.

How can researchers effectively use LAMA1 antibodies to investigate developmental processes?

LAMA1's critical role in development requires specialized methodological approaches:

• Developmental timing analysis: Search result reveals LAMA1's importance "for cerebellar development" with specific temporal expression patterns, suggesting researchers should perform time-course studies spanning embryonic through postnatal stages.

• Signaling pathway investigation: Result shows that "LAMA1 is essential for the proliferation of GCPs via activation of the Akt signaling pathway," indicating researchers should combine LAMA1 antibody studies with phospho-Akt analysis.

• Cell-type specific co-localization: For developmental studies, perform triple immunofluorescence with LAMA1 antibodies plus cell-type specific markers and proliferation markers (e.g., Ki67).

• In vitro developmental models: Use LAMA1 antibodies to monitor expression in cerebral organoids or neurosphere development.

• Quantitative morphometric analysis: Measure dendritic arborization and axon formation in the presence of LAMA1 antibody blockade, as result notes "LAMA1 deficiency can lead to alteration in cytoskeletal dynamics, which may invariably lead to alteration in dendrite growth and axonal formation."

What techniques should be employed when using LAMA1 antibodies for investigating extracellular matrix organization?

LAMA1's critical role in ECM organization requires specialized methodological approaches:

• Super-resolution microscopy: Standard fluorescence microscopy cannot resolve fine ECM structures; techniques like STORM or STED microscopy provide superior resolution of LAMA1 arrangement within basement membranes.

• Combined ECM protein detection: LAMA1 functions within a complex network of proteins. Result notes it "interact[s] with other extracellular matrix components." Design experiments with multiple antibodies targeting LAMA1, nidogen, and other laminin chains for comprehensive analysis.

• Live imaging approaches: Use non-blocking fluorescently-conjugated LAMA1 antibody fragments to visualize ECM dynamics in living systems.

• Mechanical property correlation: Combine LAMA1 immunostaining with atomic force microscopy measurements of tissue stiffness to correlate protein distribution with mechanical properties.

• Decellularization techniques: For pure ECM analysis, optimize decellularization protocols that preserve LAMA1 epitopes while removing cellular components.

What are the critical considerations for using LAMA1 antibodies in flow cytometry applications?

Flow cytometric detection of LAMA1 requires specific methodological adaptations:

• Fixation and permeabilization optimization: Search result specifies cells "were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005)" for intracellular LAMA1 detection.

• Antibody titration: Due to LAMA1's large size and complex conformation, standard titration curves should be expanded to include higher antibody concentrations than typically used for smaller proteins.

• Compensation considerations: When multiplexing, LAMA1's high abundance in certain cells may require adjustment of voltage settings and careful compensation to avoid spillover.

• Positive control selection: Result identifies U2OS human osteosarcoma cell line as a reliable positive control for LAMA1 expression, while A549 human lung carcinoma serves as a negative control.

• Validation approach: Confirm specificity by demonstrating signal reduction following LAMA1 siRNA knockdown.

How should researchers approach LAMA1 antibody selection for studying splice variants or post-translational modifications?

Investigating LAMA1 complexity requires careful antibody selection strategies:

• Epitope mapping: Select antibodies targeting regions that differentiate specific splice variants. For example, search result specifies an antibody targeting "Leu22-Met269" of human Laminin alpha 1, while result targets "amino acids 600-700."

• Modification-specific antibodies: For PTM studies, use modification-specific antibodies (e.g., phospho-LAMA1, glycosylated LAMA1) in conjunction with pan-LAMA1 antibodies.

• Mass spectrometry validation: Confirm antibody-detected modifications through parallel mass spectrometry analysis of immunoprecipitated LAMA1.

• Sequential immunoprecipitation: For complex studies, perform sequential IP with different LAMA1 antibodies to isolate specific subpopulations.

• Domain-specific functional studies: Select antibodies targeting specific functional domains (like the N-terminal Laminin VI domain mentioned in result ) when investigating particular functional aspects.